ONCAlert | Upfront Therapy for mRCC

Renal Cell Carcinoma VIEW MORE >>

Findings from a planned interim analysis of the Ib/II Study 111 showed that lenvatinib plus pembrolizumab induced a disease control rate of 94% in patients with metastatic clear cell RCC who had disease progression following treatment with a PD-1/PD-L1 inhibitor.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.